0.685
-0.115 (-14.38%)
-0.115 (-14.38%)
Upgrade to Real-Time
Afterhours (Closed)
Volume | 3,124,376 |
|
|||||
News | - | ||||||
Day High | 0.77989 | Low High |
|||||
Day Low | 0.6434 |
Company Name | Stock Ticker Symbol | Market | Type |
---|---|---|---|
Aridis Pharmaceuticals Inc | ARDS | NASDAQ | Common Stock |
Open Price | Low Price | High Price | Close Price | Prev Close |
---|---|---|---|---|
0.7564 | 0.6434 | 0.77989 | 0.7099 | 0.80 |
Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
---|---|---|---|---|---|
8,617 | 3,124,376 | $ 0.7041588 | $ 2,200,057 | - | 0.5722 - 2.94 |
Last Trade Time | Type | Quantity | Stock Price | Currency |
---|---|---|---|---|
19:59:56 | 99 | $ 0.685 | USD |
Aridis Pharmaceuticals Inc Financials
Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
---|---|---|---|---|---|---|
$ 17.79M | 25.97M | 24.53M | $ - | $ - | -3.65 | -0.50 |
Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
---|---|---|---|---|---|
- | $ - | - | 122.00k | 5.60% |
Aridis Pharmaceuticals News
Loading Messages....
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ARDS Price Data
Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
---|---|---|---|---|---|---|---|
1 Week | 1.28 | 1.45 | 0.5722 | 1.04 | 7,867,863 | -0.595 | -46.48% |
1 Month | 0.925 | 1.7458 | 0.5722 | 1.06 | 2,305,891 | -0.24 | -25.95% |
3 Months | 0.96 | 1.7458 | 0.5722 | 1.05 | 807,559 | -0.275 | -28.65% |
6 Months | 1.40 | 2.77 | 0.5722 | 1.14 | 468,614 | -0.715 | -51.07% |
1 Year | 2.16 | 2.94 | 0.5722 | 1.64 | 536,624 | -1.48 | -68.29% |
3 Years | 7.42 | 10.18 | 0.5722 | 2.22 | 309,460 | -6.74 | -90.77% |
5 Years | 13.02 | 13.85 | 0.5722 | 2.34 | 213,439 | -12.34 | -94.74% |
Aridis Pharmaceuticals Description
Aridis Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is engaged in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. |